|

Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

RECRUITINGSponsored by University of Alabama at Birmingham
Actively Recruiting
SponsorUniversity of Alabama at Birmingham
Started2023-05-01
Est. completion2028-01
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05898477

Summary

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with lymphoma that are fulfilling at least one of the following:

A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL)

Exclusion Criteria:

* Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas)
* Patients with incomplete treatment and response documentation

Conditions3

CancerHemophagocytic LymphohistiocytosesLymphoma

Locations1 site

University of Alabama at Birmingham
Birmingham, Alabama, 35294
Gaurav Goyal, MD2059346770ggoyal@uabmc.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.